以STAT3为靶标的抗肿瘤药物高通量筛选模型的建立和应用

The Establishment and Application of a High Throughput Screening Model for Inhibitors of STAT3

旨在建立稳定可靠的以转导与转录激活子(STAT3)为靶标的抗肿瘤高通量筛选模型,应用该模型筛选潜在的抗癌药物。利用基因重组、蛋白表达纯化技术,获得STAT3目的蛋白,使用酶联免疫吸附法(ELISA)进行高通量药物筛选,将筛选出的抑制剂在细胞水平上利用MTT比色法测定化合物对癌细胞增殖的影响。结果显示,成功构建表达载体pET-28a-STAT3;所建立的模型稳定可行,可用于以STAT3为靶标的抗肿瘤药物的高通量筛选;用该模型对8 248个样品进行筛选,在500μmol/L药物浓度下,化合物MDC6抑制率为92%,另外,进行IC50值的测定时,分子水平上最低达到3.37μmol/L,在细胞水平上可达到15.92μmol/L。建立的高通量药物筛选模型,具有操作方便、成本低、结果稳定等特点,可用于STAT3抑制剂的大规模筛选。

It was to establish a viable high-throughput drug screening model for discovering inhibitors of Signal Transducer and Activator of Transcription3, and applied the model to screen potential anti-cancer drugs. The STAT3 gene was amplified with PCR and cloned into the expression vector pET-28a. The recombinant STAT3 was over-expressed and purified, and then was used to bind with specific phosphotyrosine peptides. We established a high-throughput drug screening model based on ELISA to obtain some effective compounds. Further, we tested the effect of them on the growth ability and proliferation of the Hepatoma cells using MTT assay. Results showed that it was not only successfully constructed the expression vector pET-28a-STAT3, but also established a reliable and stable model for drug screening. Besides, 8 248 samples were screened, and a positive sample MDC6 was finally obtained. When the drug concentration was less than 500μmol/L, the inhibition rate of MDC6 reached 92%. The minimum value of IC50 was 3.37μmol/L, while at the cellular level it was 15.92μmol/L. In this work, we developed a repeatable and reliable assay for screening of STAT3 inhibitors.